×

Biotech and Pharmaceuticals Pharmaceuticals

  • President Donald Trump thanked two major drug companies on Thursday for not raising their prices and said his administration was working toward substantially cutting prescription-drug prices. "Thank you to Novartis for not increasing your prices on prescription drugs. Earlier this month Trump was able to persuade Pfizer CEO Ian Read to defer the...

  • President Donald Trump on Thursday thanked two major drug companies for not raising their prices and said his administration was working toward "substantially" cutting prescription-drug prices. "Thank you to Novartis for not increasing your prices on prescription drugs. We are making a big push to actually reduce the prices, maybe substantially, on...

  • Alexander J. Denner, Founding Partner and CIO, Sarissa Capital Management 

    The hedge fund manager spoke at the Delivering Alpha Conference in New York on Wednesday.

  • LONDON, July 18- AstraZeneca is increasing stockpiles of those medicines in Britain and Europe that could be affected by Brexit by around 20 percent, in preparation for potential disruption if the UK crashes out of the EU without a deal. The move affects drugs made in Britain that could be exported to Europe and supplies in the European Union that may be headed the...

  • LONDON, July 18- AstraZeneca is increasing stockpiles of those medicines in Britain and Europe that could be affected by Brexit by around 20 percent, in preparation for potential disruption if the UK crashes out of the EU without a deal. The move affects drugs made in Britain that could be exported to Europe and supplies in the European Union that may be headed the...

  • Novartis CEO

    Vas Narasimhan speaks about Novartis' pricing policy in the United States.

  • Cramer's charts suggest big-name biotech stocks Gilead and Celgene have more room to run

    Jim Cramer and technician Bob Lang inspect the charts to see if big-cap biotechnology stocks like Gilead and Celgene could have more room to run.

  • Charts: Gilead and Celgene have more room to run

    Jim Cramer and technician Bob Lang inspect the charts to see if big-cap biotechnology stocks like Gilead and Celgene could have more room to run.

  • Gilead Sciences Inc

    Jim Cramer and technician Bob Lang inspect the charts to see if big-cap biotechnology stocks like Gilead and Celgene could have more room to run.

  • New healthcare model: Pay only when the drug works?

    Companies are looking into a new model requiring payment for pharmaceutical drugs only when they work. Fred Hassan, Caret Group Founder and Chairman and former Schering-Plough CEO, joins CNBC's Meg Tirrell, Mike Santoli, Wilfred Frost, and Sara Eisen to discuss how practical it is.

  • Companies test linking drug prices to performance

    Insurers and companies are looking into a new arrangement that would require patients to only pay for pharmaceutical drugs when they work. CNBC's Meg Tirrell reports.

  • *EMA says working to assess long term risk to patients. LONDON, July 17- A common blood pressure and heart drug manufactured in bulk by a Chinese company and sold worldwide may have contained an impurity linked to cancer since 2012, European regulators said on Tuesday. The European Medicines Agency, which first raised the alarm over the Chinese supplied...

  • U.S. regulators proposed new guidelines Tuesday to make it easier for some common medicines to be sold without a prescription— and more convenient for consumers to get them. The Food and Drug Administration is evaluating ways to make sure patients don't take an inappropriate over-the-counter drug, Commissioner Scott Gottlieb said in a statement.

  • Johnson & Johnson CFO on Q2 earnings beat

    Joseph Wolk, Johnson & Johnson CFO, breaks down the company's quarterly numbers which beat on the top and bottom line, helped by improved cancer drug sales.

  • ZURICH, July 17- Swiss drugmaker Roche's hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed its new medicine reduced symptoms in people at high risk of complications. The anti-viral medicine, also called Xofluza, is approved in Japan. U.S. regulators have accelerated their review and could...

  • Drugs and money

    Some drug companies continue to raise prices, despite mounting public scrutiny and pressure from the president, a move one analyst says "makes no sense."  

  • Drugmakers will think twice on price increases after Trump's Pfizer skirmish, says analyst

    Elliot Wilbur, Raymond James specialty pharmaceuticals analyst, discusses the rising cost of prescription drugs and how President Trump is tackling the issue.

  • July 13- A U.S. court has granted Indivior a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States, Indivior said on Friday. Reddy's and U.S.-based Mylan NV got approval from the Food and Drug Administration last month to sell...

  • July 13- A U.S. court has granted Indivior a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States. The ruling comes days after Indivior scrapped its full-year guidance citing an "accelerated" loss in U.S. market share to the...

  • Johnson and Johnson ordered to pay $4.7 billion in asbestos case

    A St. Louis jury on Thursday found Johnson & Johnson liable and ordered them to pay over $4.5 billion to 22 women who claimed the company's baby powder gave them cancer. Vamil Divan, Credit Suisse, explains what that could mean for they company's stock.